All In Biotech

Drug Trial Radar · NCT05546879

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

43

Actual

Start

Mar 15, 2023

Primary completion

Mar 19, 2026

Study completion Mar 19, 2029

Sponsor

Lead sponsor
University Hospital, GrenobleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NETRIS Pharma
First posted
Sep 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in first line setting in patients with unresectable hepatocellular carcinoma. The study drug which is tested is the NP137 in association with Atezolizumab-Bevacizumab to allow a better tumor response as well as better survival outcomes with an acceptable safety.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • NP137Drug

    NP137 at 9 or 14 mg/kg IV will be administered every 21 days.

  • AtezolizumabDrug

    Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-days cycle

  • BevacizumabDrug

    Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Proportion of patients experiencing adverse eventsTime frame: At 36 months

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Angers

    Angers, France

  • Hôpital Haut Lêveque

    Bordeaux, France

  • 12 Hôpital St Joseph

    Marseille, France

  • CHU Nantes

    Nantes, France

  • AP-HP Beaujon

    Paris, France

  • AP-HP St Antoine

    Paris, France

  • CHU Reims

    Reims, France

  • CHU Toulouse

    Toulouse, France

  • CHU de GRENOBLE ALPES

    Grenoble, Alpes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.